Insulin Strategy

Recently, the U.S. Food and Drug Administration (FDA) approved the first interchangeable biosimilar insulin product indicated to improve glycemic control in adults and pediatric patients with Type I diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee-yfgn, and its authorized alternative, insulin glargine-yfgn, are biosimilars and interchangeable with Lantus, a long-acting insulin analog. Semglee-yfgn and insulin glargine-yfgn will be available on the market by the end of 2021. These new interchangeable biosimilar insulin products offer additional safe and cost-effective options for management of diabetes.

Effective January 1, 2022, Semglee-yfgn and Insulin glargine-yfgn will replace Lantus on Blue Cross Blue Shield of North Dakota (BCBSND) formularies. Lantus will be removed from formulary and will be subject to Coverage Exception and/or Prior Approval. Utilization Management policies will be updated to reflect the formulary changes and will be available for review on January 1, 2022.